AB0635 HAEMATOLOGICAL MANIFESTATIONS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: REAL WORLD DATA FROM A CENTRE IN NORTHERN ITALY

Background Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder characterized by variety of signs and symptoms; it manly affects women childbearing age, with an estimated prevalence 24/100,000 people in Europe North America. Among other clinical manifestations, haematological involvement one the most common SLE as includes anaemia, leukopenia, lymphopenia, thrombocytopenia, lymphadenopathy splenomegaly; furthermore, usually challenging to discriminate whether such manifestations are caused disease or immunosuppressants. To date, few studies tried evaluate them using real world data. Objectives patients Methods A retrospective study was performed gathering 2019 EULAR/ACR Classification Criteria for were used discern involvements diagnosis SLE; thrombocytopenia haemolytic anaemia (AIHA) considered this study. Six subgroups formed each condition alone their combinations analyzed. Logistic regression calculate odds ratio (OR) 95% confidence interval (CI) chosen assess statistical significance. Results One hundred forty-two affected enrolled (N=142); among these, thirty met inclusion criteria (n=30, 52 ±12.4 years, 28 F, 2 M). Three showed AIHA (10.0%), six had only (20.0%) 8 displayed leukopenia (26.7%). Thirteen combination 6 both 4 manifested association (13.3%); lastly, 3 (10.0%). The latter proved be manifestation present 15 out 30 (50.0%) (Figure 4). Azathioprine (AZA), hydroxychloroquine (HCQ), (26.6%), while Mycophenolate Mofetil (MMF) HCQ found 5 (16.7%); seventeen received either biologic drug (Belimumab). therapy AZA MMF, former more frequently associated vs MMF (OR 1 =2.5); however, result not statistically significant (CI 0.77; 8;04); similar observed when compared + Belimumab =1.16, OR =0.46, respectively) since they did reach Conclusion In preliminary study, real-world data essential analyze SLE. many frequent agreement published literature, strictly followed AIHA. linked higher percentage therapies but significant. This has some limitations (number patients, possible selection bias) which require further evaluations properly assessed. References [1]Mariëlle et al, Incidence invasive pneumococcal immunocompromised Travel Medicine Infectious Disease, 2018 [2]Levine AB Clinical assessment management cytopenias patients. Curr Rheum Rep. 2011 Acknowledgements: NIL. Disclosure Interests None Declared.